Products

Our pipeline: Delivering first-in-class immunotherapies of activation and regulation

 

Four clinical assets

  • Immuno-Oncology
  • Immuno-Inflammation
Product candidate
Indication (targets)
Research
IND-enabling
Phase 1
Phase 2
Phase 3
NSCLC post-ICI
NSCLC Combo 2L post-ICI
PDAC Combo maintenance
OC Mono or Combo
UC
Solid tumors
KIdney transplant
HNSCC 2L and HCC 1L/2L
Solid tumors
Chronic inflammation

Significant partnerships with AbbVie, Boehringer Ingelheim, Veloxis Pharmaceuticals and CKD for up to €2.1 billion in milestones (€180 million already received)

Our portfolio of clinical assets and research platforms

In Immuno-Oncology and Immuno-Inflammation

To receive OSE Immunotherapeutics’ latest news